Mevion Medical Systems
U.S. proton-therapy specialist focused on compact single-room proton-therapy systems. Privately held; established the U.S.-vendor presence in compact proton therapy alongside IBA (Proteus ONE). Smaller installed base than IBA globally but distinctive in U.S. community-hospital proton programs.
Company history
- 2004 — founded as Still River Systems; renamed Mevion Medical Systems.
- 2013 — first clinical Mevion S250 install (Barnes-Jewish Hospital, St. Louis).
- 2010s — Mevion S250 / S250i compact-proton systems established the single-room U.S. proton-therapy category.
- 2020s — HYPERSCAN pencil-beam-scanning advanced delivery; ongoing single-room compact-proton expansion.
Product line
- Mevion S250 — original compact single-room proton-therapy system; superconducting synchrocyclotron mounted directly on the gantry.
- Mevion S250i — refresh generation.
- Mevion S250-FIT — current; HYPERSCAN pencil-beam-scanning compact configuration.
Distinctive technology
- Gantry-mounted synchrocyclotron — compact superconducting accelerator integrated with the rotating gantry, eliminating the separate cyclotron vault and beamline transport. The architectural approach that made single-room proton therapy possible at community-hospital scale.
- HYPERSCAN pencil-beam scanning — current-generation modulated-spot delivery with rapid energy switching.
- Single-room footprint — substantially smaller building footprint than multi-room proton centers (Proteus PLUS, Hitachi multi-room).
Market position
Compact single-room proton therapy specialist. Direct competitor: IBA Proteus ONE. Larger multi-room competitors include IBA Proteus PLUS, Hitachi proton-therapy systems, and Varian ProBeam.
Refurb posture
- No meaningful refurb market — proton-therapy installed base is small and per-vendor; lifecycle decisions are program-level. Service-contract continuity dominates.
- HYPERSCAN-era systems are current-generation; pre-HYPERSCAN S250 / S250i installs may face evolving service-support timelines.